Better coordinated vaccine strategies are urgently needed to combat the spread of peste des petits ruminants (PPR); a neglected but devastating livestock disease which now poses a threat to sheep and goat populations in Europe, say scientists from The Pirbright Institute.
Leading scientists at The Pirbright Institute have welcomed the confirmation of funding for its key scientific research programmes for the next five years from the Biotechnology and Biological Sciences Research Council (BBSRC), which was officially announced today.
Pirbright is an international centre of scientific excellence in the study of livestock diseases and is at the forefront of those organisations protecting the UK from the potentially devastating social and economic impact such diseases can have on the nation’s farming industry and food supply.
Dr. Bryan Charleston, has been appointed as Institute Director for The Pirbright Institute, a world-leading centre for the prevention and control of viral diseases of livestock, which receives strategic investment from the Biotechnology and Biological Sciences Research Council (BBSRC).
Scientists have made a breakthrough in the search for an effective vaccine for bovine respiratory syncytial virus (bRSV), which could also be effective against the human form of the disease that can be dangerous for infants and the elderly.
HRH The Princess Royal officially opened the BBSRC National Vaccinology Centre: The Jenner Building today (24 March, 2017) – a world leading vaccine development facility, located at The Pirbright Institute in Surrey.
The Pirbright Institute is to play a key role in a new international project funded by the European Commission, to fight the mosquito-transmitted diseases now threatening Europe.
The Infravec2 Project is an international consortium of 24 partner institutions coordinated by the Institut Pasteur, Paris.
A student studying for his PhD at The Pirbright Institute was named Young Innovator of the Year at the Guildford Innovation Awards 2017 on 22 February 2017. Tom Whitehead won the award for his research on egg anti-viral proteins which could lead to a major step forward in vaccine production rates.
The American Association for the Advancement of Science (AAAS) has selected a senior scientist at The Pirbright Institute as a 2017-2018 AAAS Alan I. Leshner Leadership Institute Public Engagement Fellow.
Scientists at The Pirbright Institute have used genetic engineering to develop a more efficient and effective vaccine for Marek’s disease which could pave the way for a new generation of poultry disease vaccines.
The Pirbright Institute is one of the largest recipients of the Government’s new £120 million fund to fight deadly diseases – winning £1.580 million with its partners, for a joint project to develop a safe and effective livestock vaccine against Rift Valley fever.